GXNPC 1
Alternative Names: Adipose-tissue-derived-stem-cells-Gwo-Xi; ADSCs-Gwo-Xi; Autologous-ADSCs-Gwo-Xi; GXNPC1; hADSCs-Gwo-XiLatest Information Update: 26 Jul 2022
Price :
$50 *
At a glance
- Originator GWOXI Stem Cell Applied Technology
- Class Cardiovascular therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Stroke
Most Recent Events
- 26 Jul 2022 Phase-II development is ongoing in Taiwan (NCT04088149) (Gwo Xi Stem Cell Applied Technology pipeline, July 2022)
- 06 Feb 2020 Phase-II clinical trials in Stroke (In the elderly) in Taiwan (Parenteral, Injection) (NCT04088149)
- 12 Sep 2019 Gwo Xi Stem Cell Applied Technology plans a phase II trial for Stroke (In the elderly), in November 2019 , (NCT04088149)